GlaxoSmithKline Pharmaceuticals Limited (GSK Pharma) reported strong Q4 results with a 31.50% year-over-year increase in consolidated net profit to ₹2.63 billion. Revenue grew by 4.73% to ₹9.74 billion. The board recommended a final dividend of ₹42.00 per equity share. The company's performance shows significant growth in both revenue and profit, indicating effective cost management and operational efficiency in the Indian market.
GlaxoSmithKline Pharmaceuticals Limited (GSK Pharma) announced impressive Q4 FY2025 results with revenue increasing to ₹966.00 crore, up 6.04% year-over-year. Full-year revenue for FY2025 reached ₹3,723.00 crore, a 9.00% increase from the previous year. The company plans to launch two oncology assets, Zejula and Jemperli, in FY2025-26. The board has recommended a final dividend of ₹42.00 per equity share.
18Feb 25
GlaxoSmithKline Pharmaceuticals Soars 17% on Stellar Q3 FY25 Performance
GlaxoSmithKline Pharmaceuticals' share price surged 17% following the release of its Q3 FY25 results. The company reported a 400% increase in consolidated net profit to ₹230 crore, an 18% rise in revenue to ₹949.42 crore, and an expanded EBITDA margin of 30.7%. The stock has rallied 36% over three days, reflecting strong investor confidence in the company's performance and growth prospects.